Substance / Medication

Buspirone

Overview

Active Ingredient
buspirone
RxNorm CUI
1827

Indications

TM Bucapsolcapsules are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. 1 The efficacy of buspirone hydrochloride has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depr

Labeler: PANGEA PHARMACEUTICALS, LLCUpdated: 2025-12-23T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

TM Bucapsolcapsules are contraindicated in patients hypersensitive to buspirone hydrochloride. WARNINGS DOSAGE AND ADMINISTRATION DRUG INTERACTIONS ,and The use of monoamine oxidase inhibitors (MAOIs) intended to treat depression with buspirone or within 14 days of stopping treatment with buspirone

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

48 trials linked to this intervention

48
Total Trials
5
Recruiting
17
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Effect of Buspirone on Upper Gastrointestinal Disorders of Gut-Brain Interaction: A Systematic Review and Meta-analysis.
Mohamedali Zahra, Amarasinghe Gehanjali, Hopkins Christopher W P et al. · J Neurogastroenterol Motil · 2025
PMID: 39779200Meta-AnalysisFull text (PMC)
The behavioural effects of the serotonin 1A receptor agonist buspirone on cognition and emotional processing in healthy volunteers.
Smith Alexander L W, Hamilton Sorcha, Murphy Susannah E et al. · Psychopharmacology (Berl) · 2025
PMID: 40087174RCTFull text (PMC)
Buspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study.
LeWitt Peter A, Stebbins Glenn T, Christensen Kenneth Vielsted et al. · Mov Disord · 2024
PMID: 38314643RCT
Buspirone for early satiety and symptoms of gastroparesis: A multi-centre, randomised, placebo-controlled, double-masked trial (BESST).
Parkman Henry P, Yates Katherine P, Sarosiek Irene et al. · Aliment Pharmacol Ther · 2023
PMID: 37052334RCTFull text (PMC)
Gastric Glitch: A New Functional Disease Treated with Buspirone and Prucalopride in an N-of-1 Double-Blind Clinical Trial.
Ambrós Gabriela, Valões Ricardo, Dos Santos Carregosas Ana Luísa et al. · Clin Drug Investig · 2023
PMID: 36370320RCT
Benefit of buspirone on chemoreflex and central apnoeas in heart failure: a randomized controlled crossover trial.
Giannoni Alberto, Borrelli Chiara, Mirizzi Gianluca et al. · Eur J Heart Fail · 2021
PMID: 32441857RCT
Buspirone decreases susceptibility to hypocapnic central sleep apnea in chronic SCI patients.
Maresh Scott, Prowting Joel, Vaughan Sarah et al. · J Appl Physiol (1985) · 2020
PMID: 32816639RCTFull text (PMC)
Comparison of the Efficacy of Buspirone and Placebo in Childhood Functional Abdominal Pain: A Randomized Clinical Trial.
Badihian Negin, Yaghini Omid, Badihian Shervin et al. · Am J Gastroenterol · 2020
PMID: 32221160RCT
A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability.
Schneider Ruth B, Auinger Peggy, Tarolli Christopher G et al. · Parkinsonism Relat Disord · 2020
PMID: 33070009RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Buspirone (substance)
SNOMED CT
387523009
UMLS CUI
C0006462
RxNorm CUI
1827
Labeler
PANGEA PHARMACEUTICALS, LLC

Clinical Data

This intervention maps to 11 entities in the Ltrl knowledge graph.

3
Conditions
4
Biomarkers
2
Specialists
0
Symptoms
48
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.